Let's hope the THI is 'committed' to supporting Rexlemestrocel-L (aka Revascor) for the treatment of hypoplastic left heart syndrome (HLHS) ... a rare pediatric condition. Their involvement would likely help support the FDA AA pathway in this instance if this was in fact being considered
GLTAH
"THI is committed to bringing the future of cardiovascular health to life, and that includes supporting research & innovation for rare heart conditions."
Cell Therapy News/Articles, page-17488
-
- There are more pages in this discussion • 336 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
0.005(0.43%) |
Mkt cap ! $1.318B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.17 | $1.13 | $3.743M | 3.261M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 78561 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 114667 | 4 |
View Market Depth
| Last trade - 16.10pm 22/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |